Rifadin (rifampin) capsules, USP, 150 mg, 100-count capsules per bottle, Manufactured by: Fabrique par Sanofi-Aventis Canada Inc., Laval, Quebec, Canada H7L4A8, DIN # 02091887
Published August 21, 2013 · Recall initiated: February 26, 2013
Summary
FDA records drug Class II recall D-886-2013, published August 21, 2013 and initiated February 26, 2013. Recalling firm: Sanofi-Synthelabo; Status: Terminated; Reported quantity: 998 Bottles; Lot: Lot # 3099036, Exp 03/2014. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which was related to an issue detected with the encapsulating equipment.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Sanofi-Synthelabo
- Distributor
- Canada
- Lot
- Lot # 3099036, Exp 03/2014
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- Canada
Related recalls
- FDAGastrografin (Diatrizoate Meglumine and Diatrizoate Sodium Solution), USP, 37% Organically Bound Iodine, 120August 21, 2013
- FDAPropofol Injectable Emulsion, 1%, 1 g/100 mL (10 mg/mL), 100 mL, Single patient infusion vial, RX only,August 21, 2013
- FDARanitidine Hydrochloride Tablets, USP, 150 mg, OTC, a) Equate brand Maximum Strength Acid Reducer, 65 countAugust 21, 2013
- FDAClobetasol Propionate Cream, USP, 0.05%, 15 grams, Rx only, Hi-Tech PHARMACAL label, Hi-Tech Pharmacal, Co.,August 21, 2013
- FDABelladonna Alkaloids with Phenobarbital Tablets, 1000 count (NDC 0143-1140-10) and 5000 count (NDCAugust 21, 2013
- FDA3M Tekk Brand Industrial/Construction First Aid Kit, Total Resources Int'l Walnut, CA 91789August 21, 2013
Questions about this recall
Was Rifadin (rifampin) capsules, USP, 150 mg, 100-count capsules per bottle, Manufactured by: Fabrique par Sanofi-Aventis Canada Inc., Laval, Quebec, Canada H7L4A8, DIN # 02091887 recalled?
Yes. FDA published recall D-886-2013 on August 21, 2013. Reported hazard: Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which was related to an issue detected with the encapsulating equipment.
What should I do if I have this product?
Voluntary: Firm initiated · Letter